-
公开(公告)号：US11213486B2
公开(公告)日：2022-01-04
申请号：US16313607
申请日：2018-01-10
发明人： Kiichiro Nabeta
IPC分类号： A61K9/107 , A61K47/46 , A61K47/10 , A61K47/32 , A61K31/573 , A61K47/18 , A61K47/44 , A61K47/12 , A61K47/26 , A61K47/38 , A61K47/36 , A61K47/14 , A61K47/24 , A61K9/00 , A61K47/34
摘要： The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.
-
公开(公告)号：US20190160008A1
公开(公告)日：2019-05-30
申请号：US16313607
申请日：2018-01-10
发明人： Kiichiro NABETA
IPC分类号： A61K9/107 , A61K47/46 , A61K47/10 , A61K47/32 , A61K47/38 , A61K47/18 , A61K47/44 , A61K47/12 , A61K47/26
摘要： The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.
-
3.发明申请METHOD FOR SUPPRESSING ONSET OF GASTRIC ULCER AS ADVERSE EFFECT OF DRUG, ORAL PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ONSET OF GASTRIC ULCER AND METHOD FOR PRODUCING THE SAME 审中-公开用于抑制胃溃疡发生的方法作为药物不良反应的作用，口服药物组合物用于抑制胃溃疡的发生及其生产方法公开(公告)号：US20160287627A1
公开(公告)日：2016-10-06
申请号：US15037404
申请日：2014-11-19
发明人： Shuta FURUKI , Hideto YOSHIDA , Kiichiro NABETA
IPC分类号： A61K31/728 , A61K9/06 , A61K31/405 , A61K31/192 , A61K31/616 , A61K9/00 , A61K31/196
CPC分类号： A61K31/728 , A61K9/0053 , A61K9/0095 , A61K9/06 , A61K9/205 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/616 , A61K31/723 , A61K47/36
摘要： [Problem] To suppress the onset of adverse effects of drugs that cause gastric ulcers as an adverse effect.[Solution] The onset of gastric ulcers induced by a drug is suppressed by incorporating, into a pharmaceutical composition containing a drug having gastric ulcers as an adverse effect, a high-molecular polysaccharide that has a molecular weight of 800,000-3,000,000 and that produces a gel when a 0.3% aqueous solution thereof is added dropwise to artificial gastric juice.
摘要翻译： [解决方案]通过将含有胃溃疡药物作为副作用的药物组合物掺入分子量为800,000-3,000,000的高分子多糖中，可以抑制由药物引起的胃溃疡的发作， 将其0.3％的水溶液滴加到人造胃液中的凝胶。
-
公开(公告)号：US20210069110A1
公开(公告)日：2021-03-11
申请号：US16499726
申请日：2018-03-31
发明人： Kiichiro NABETA
摘要： An object of the present invention is to provide a non-aqueous composition having a drug carried therein, the composition being capable of preparing a drug-containing fat emulsion that is usable as an injection, an eye drop, a nasal drop, an inhalant, or the like by being mixed with an aqueous medium in use without producing a drug-containing fat emulsion in advance, and a method for producing the non-aqueous composition. The non-aqueous composition having a drug carried therein of the present invention as a resolution for achieving the object is characterized by comprising an oil or fat, a slightly water soluble drug, and an emulsifier which are dissolved in a polyhydric alcohol as a water soluble carrier at a content of the oil or fat of 0.05 to 250 mg/g, a weight ratio of the slightly water soluble drug to the oil or fat (slightly water soluble drug/(oil or fat)) of 0.0001 to 50 (provided that the total content of the slightly water soluble drug and the oil or fat is at most 300 mg/g), and a content of the emulsifier of 20 to 500 mg/g.
-
公开(公告)号：US20180177820A1
公开(公告)日：2018-06-28
申请号：US15739229
申请日：2016-10-13
发明人： Kiichiro NABETA
IPC分类号： A61K31/728 , A61K9/14 , A61K31/192 , A61K31/196 , A61K31/573 , A61K9/00
CPC分类号： A61K31/728 , A61K9/0007 , A61K9/0053 , A61K9/0065 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2031 , A61K9/485 , A61K9/4866 , A61K31/047 , A61K31/192 , A61K31/196 , A61K31/573 , A61K31/722 , A61K31/723 , A61K31/726 , A61K33/10 , A61P1/00 , A61K2300/00
摘要： An object of the present invention is to provide a protective composition for gastrointestinal mucosa, for example, for inhibiting occurrence of a gastrointestinal mucosa disorder when an oral drug that induces the gastrointestinal mucosa disorder is taken. The protective composition for gastrointestinal mucosa of the present invention as a resolution for achieving the object is characterized by comprising at least a macromolecular polysaccharide, sodium hydrogen carbonate and/or magnesium carbonate, and a polyhydric alcohol. According to the protective composition for gastrointestinal mucosa of the present invention, sodium hydrogen carbonate or magnesium carbonate foams through contact with a gastric juice in stomach to thereby generate diffusing power for the macromolecular polysaccharide. This power can allow the macromolecular polysaccharide to quickly dissolve or disperse in the gastric juice and allow the macromolecular polysaccharide to effectively exert a gastric mucosa protective action. In addition, the macromolecular polysaccharide dissolved or dispersed in the gastric juice moves into intestine without degradation in stomach, then dissolves in an intestinal juice having a neutral or alkaline pH, and exerts an intestinal mucosa protective action without degradation also in intestine. The polyhydric alcohol plays a role as a dispersion medium for the macromolecular polysaccharide and sodium hydrogen carbonate or magnesium carbonate which are powder, or enables formulation of the protective composition for gastrointestinal mucosa of the present invention into various dosage forms, according to the nature and use amount thereof.
-
公开(公告)号：US09427435B2
公开(公告)日：2016-08-30
申请号：US14492509
申请日：2014-09-22
发明人： Kiichiro Nabeta , Toru Hibi
IPC分类号： A61K31/4468 , A61P29/00 , A61K9/00 , A61K9/107 , A61K47/10 , A61K47/24 , A61K47/12 , A61K47/44
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
公开(公告)号：US20150141461A1
公开(公告)日：2015-05-21
申请号：US14492509
申请日：2014-09-22
发明人： Kiichiro Nabeta , Toru Hibi
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
